Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HEPATITIS C VIRUS CHRONIC INFECTION”

1,453 trials

Showing 20 of 1,453 results

Testing effectiveness (Phase 2)Study completedNCT00433069
What this trial is testing

Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Who this might be right for
Chronic Hepatitis C
University Hospital, Geneva 5
Not applicableWithdrawnNCT01691235
What this trial is testing

SIMpill Medication Dispensing Device in the Treatment of HCV

Who this might be right for
Chronic Hepatitis C Virus
University of Chicago
Testing effectiveness (Phase 2)Ended earlyNCT02759315
What this trial is testing

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

Who this might be right for
Hepatitis C, Chronic
Merck Sharp & Dohme LLC 160
Large-scale testing (Phase 3)Study completedNCT02203149
What this trial is testing

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

Who this might be right for
Hepatitis C
Merck Sharp & Dohme LLC 399
Post-approval studies (Phase 4)UnknownNCT00526448
What this trial is testing

Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients

Who this might be right for
Chronic Hepatitis C
Hospital Carlos III, Madrid 384
Testing effectiveness (Phase 2)Study completedNCT01528735
What this trial is testing

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Who this might be right for
Hepatitis C, Chronic
Boehringer Ingelheim 25
Testing effectiveness (Phase 2)Study completedNCT01717326
What this trial is testing

The Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

Who this might be right for
Hepatitis C
Merck Sharp & Dohme LLC 573
Testing effectiveness (Phase 2)Study completedNCT01581138
What this trial is testing

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Who this might be right for
Chronic Hepatitis C Virus
Vertex Pharmaceuticals Incorporated 64
Not applicableStudy completedNCT02581189
What this trial is testing

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Who this might be right for
Chronic Hepatitis C
AbbVie 565
Not applicableUnknownNCT00272389
What this trial is testing

Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile

Who this might be right for
Hepatitis C Virus Chronic Infection
Hadassah Medical Organization 150
Testing effectiveness (Phase 2)UnknownNCT00332176
What this trial is testing

Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Who this might be right for
Chronic Hepatitis C
BioWest Therapeutics Inc 50
Large-scale testing (Phase 3)Study completedNCT02092350
What this trial is testing

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

Who this might be right for
Hepatitis C Virus
Merck Sharp & Dohme LLC 237
Early research (Phase 1)Study completedNCT01523990
What this trial is testing

Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

Who this might be right for
HealthyHepatitis C, Chronic
TaiGen Biotechnology Co., Ltd. 135
Large-scale testing (Phase 3)Study completedNCT02170727
What this trial is testing

A Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Who this might be right for
Hepatitis C Virus
Bristol-Myers Squibb 199
Testing effectiveness (Phase 2)Study completedNCT02340962
What this trial is testing

Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

Who this might be right for
Hepatitis C, Chronic
TaiGen Biotechnology Co., Ltd. 25
Testing effectiveness (Phase 2)Study completedNCT01710501
What this trial is testing

Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Who this might be right for
Chronic Hepatitis C (CHC)
Merck Sharp & Dohme LLC 87
Post-approval studies (Phase 4)Study completedNCT00107653
What this trial is testing

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Who this might be right for
Hepatitis C, Chronic
Hoffmann-La Roche 569
Testing effectiveness (Phase 2)Study completedNCT00991289
What this trial is testing

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Who this might be right for
HIV InfectionHepatitis C Infection
National Institute of Allergy and Infectious Diseases (NIAID) 68
Post-approval studies (Phase 4)WithdrawnNCT04614142
What this trial is testing

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Who this might be right for
End Stage Renal DiseaseChronic Hepatitis c
Massachusetts General Hospital
Large-scale testing (Phase 3)Study completedNCT01725529
What this trial is testing

An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Who this might be right for
Hepatitis C, Chronic
Janssen R&D Ireland 457
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation